Drugs / NVX-CoV2373 + NVX-CoV2540
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05372588 | May → Jul 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVX-CoV2373 + NVX-CoV2540 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05372588 ↗ |
| Route | Intramuscular | “administered via a 0·5 mL intramuscular injection (2·5 μg of NVX-CoV2373 plus 2·5 μg of NVX-CoV2540 for the bivalent vaccine, prepared on-site as a 1:1 mixture).” PMID 38460525 ↗ Mar 2024 |